Endocan: A New Molecule Playing a Role in the Development of Hypertension and Chronic Kidney Disease?

Journal of Clinical Hypertension

Volumn 16, Issue 12, 2014, Pages 914-916

  Afsar, Baris ^a   Takir, Mumtaz ^b   Kostek, Osman ^b   Covic, Adrian ^c   Kanbay, Mehmet ^d  

^a Konya Numune State Hospital   (Turkey)

^b ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^c Hospital CI Parhon   (Romania)

^d KOÇ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CELL PROTEIN; CYCLOOXYGENASE 2; ENDOCAN; ENDOTHELIAL CELL SPECIFIC MOLECULE 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; PENTRAXIN 3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ESM1 PROTEIN, HUMAN; PROTEOGLYCAN; TUMOR PROTEIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BLOOD SAMPLING; CELL ADHESION; CHRONIC KIDNEY DISEASE; CYTOSKELETON; ENDOTHELIUM CELL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; REVIEW; UPREGULATION; VASCULAR ENDOTHELIUM; VASODILATATION; CHRONIC KIDNEY FAILURE; METABOLISM;

HUMANS; HYPERTENSION; NEOPLASM PROTEINS; PROGNOSIS; PROTEOGLYCANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84919642444     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12440     Document Type: Review

References (23)

1. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271:20458-20464.
2. Béchard D, Gentina T, Delehedde M, et al. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem. 2001;276:48341-48349.
3. Zhang SM, Zuo L, Zhou Q, et al. Expression and distribution of endocan in human tissues. Biotech Histochem. 2012;87:172-178.
4. Delehedde M, Devenyns L, Maurage CA, Vivès RR. Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. IntJCell Biol. 2013;2013:705027.
5. Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70:291-296.
6. Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169:1066-1070.
7. Scherpereel A1, Depontieu F, Grigoriu B, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med. 2006;34:532-537.
8. Grigoriu BD Depontieu F Scherpereel A, et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res. 2006;12:4575-4582.
9. Maurage CA Adam E Minéo JF, et al. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol. 2009;68:633-641.
10. Kim JH, Park MY, Kim CN, et al. Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1α in human colon carcinoma: impact of ESM-1 on prognosis and its correlation with clinicopathological features. Oncol Rep. 2012;28:1701-1708.
11. Balta S, Mikhailidis DP, Demirkol S, et al. Endocan-a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65:773-777.
12. Su YH, Shu KH, Hu CP, et al. Serum endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients. Transplant Proc. 2014;46:323-327.
13. Yilmaz MI, Siriopol D, Saglam M, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014 July 2 [Epub ahead of print].
14. Tadzic R, Mihalj M, Vcev A, et al. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Press Res. 2013;37:103-115.
15. Li S, Wang L, Wang C, et al. Detection on dynamic changes of endothelial cell specific molecule-1 in acute rejection after renal transplantation. Urology. 2012;80:738-e1.
16. Béchard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167:3099-3106.
17. Abid MR, Yi X, Yano K, Shih SC, Aird WC. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res. 2006;72:136-145.
18. Lee W, Ku SK, Kim SW, Bae JS. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229:620-630.
19. Oltean S, Pullerits R, Flodén A, Olausson M, Oltean M. Increased resistin in brain dead organ donors is associated with delayed graft function after kidney transplantation. J Transl Med. 2013;11:233.
20. Shi P, Diez-Freire C, Jun JY, et al. Brain microglial cytokines in neurogenic hypertension. Hypertension. 2010;56:297-303.
21. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55:500-507.
22. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2010;298:R1089-R1097.
23. Kose M, Emet S, Akpinar TS, et al. Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology. Aug 28, 2014 [Epub ahead of print].